WAGTMANN, PETER ANDREAS NICOLAI REUMERT,SVENDSEN, IVAN,SVENSSON, ROZANA,ALIFRANGIS, LENE HJORTH,OVERGAARD, RUNE VIIG
申请号：
CA2675291
公开号：
CA2675291C
申请日:
2008.01.11
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
Inhibitory Killer lg-Like Receptors (KIRs) on NK cells inhibit the activationof NK cellcytotoxicity required to clear cancer cells and other diseased cells in asubject. An IgG4isotype anti-KIR antibody (1-7F9) overcomes the KIR-mediated inhibition of NKcell activationand, thus, potentiates NK cell-mediated cytotoxicity. The pharmacokinetics andpharmacodynamics of 1-7F9 is assessed in pre-clinical and clinical trials inorder to determinea dosing frequency that is effective to potentiate NK cell cytotoxicity (i.e.,modulate NK cellsand/or treat cancer).
